Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.

S Zoccolella, P Lamberti, E Armenise, M de Mari, S V Lamberti, R Mastronardi, A Fraddosio, G Iliceto, P Livrea

Journal: Parkinsonism & related disorders 2005;11(2):131-3

PMID: 15734674

Full Text on Elsevier Science View on PubMed

Abstract

Elevated plasma homocysteine (Hcy) concentrations have been reported in L-dopa treated Parkinson's disease (PD) patients, suggesting that L-dopa treatment is an acquired cause of hyperhomocysteinemia. Aim of this study is to evaluate the effects of different antiparkinsonian drugs on Hcy concentrations. We compared Hcy, B(12) and folate levels in 45 PD patients (15 treated with dopamine-agonists, 15 with L-dopa and 15 with L-dopa plus a catechol-O-methyltransferase-inhibitor (COMT-I) and in 15 controls. Analysis of data revealed that L-dopa administration significantly increases Hcy concentrations and that the addition of COMT-I effectively reduces the homocysteinemia.

Address: Department of Neurological Sciences, University of Bari, Ospedale Policlinico, Piazza Giulio Cesare 11, Bari 70124, Italy.

DOI: 10.1016/j.parkreldis.2004.07.008

Link outs

Free resources

Medical:

Miscellaneous:

https://assays.cancer.gov/CPTAC-482

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S1353...

MeSH Terms: Aged, Antiparkinson Agents, Catechol O-Methyltransferase Inhibitors, Dopamine Agonists, Enzyme Inhibitors, Female, Folic Acid, Homocysteine, Humans, Levodopa, Male, Middle Aged, Parkinson Disease, Vitamin B 12